CONFORTI, FABIO
 Distribuzione geografica
Continente #
AS - Asia 552
NA - Nord America 535
EU - Europa 245
SA - Sud America 120
Continente sconosciuto - Info sul continente non disponibili 98
AF - Africa 22
Totale 1.572
Nazione #
US - Stati Uniti d'America 484
SG - Singapore 236
IT - Italia 148
CN - Cina 134
BR - Brasile 92
VN - Vietnam 64
HK - Hong Kong 27
FR - Francia 22
CA - Canada 21
IN - India 21
MX - Messico 15
GB - Regno Unito 11
ID - Indonesia 11
BD - Bangladesh 9
DE - Germania 9
FI - Finlandia 9
PH - Filippine 9
AR - Argentina 8
RU - Federazione Russa 8
IE - Irlanda 7
IQ - Iraq 7
MA - Marocco 6
SA - Arabia Saudita 6
EG - Egitto 5
ES - Italia 5
JM - Giamaica 5
JP - Giappone 5
CL - Cile 4
EC - Ecuador 4
MY - Malesia 4
NG - Nigeria 4
KH - Cambogia 3
NI - Nicaragua 3
PE - Perù 3
PK - Pakistan 3
PY - Paraguay 3
QA - Qatar 3
RS - Serbia 3
TR - Turchia 3
AL - Albania 2
AT - Austria 2
BY - Bielorussia 2
CH - Svizzera 2
GT - Guatemala 2
HN - Honduras 2
NL - Olanda 2
PL - Polonia 2
PR - Porto Rico 2
UA - Ucraina 2
UY - Uruguay 2
VE - Venezuela 2
ZA - Sudafrica 2
AO - Angola 1
BG - Bulgaria 1
BO - Bolivia 1
CO - Colombia 1
CY - Cipro 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DZ - Algeria 1
GM - Gambi 1
GR - Grecia 1
HR - Croazia 1
JO - Giordania 1
KE - Kenya 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LT - Lituania 1
NP - Nepal 1
OM - Oman 1
RO - Romania 1
SE - Svezia 1
SI - Slovenia 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
Totale 1.474
Città #
Singapore 71
Milan 57
Ashburn 53
Santa Clara 47
New York 32
Beijing 31
San Jose 31
Hong Kong 27
Ho Chi Minh City 26
Buffalo 20
Los Angeles 18
Rome 18
Shanghai 18
The Dalles 18
Chandler 17
Dallas 14
Hanoi 13
São Paulo 12
Naples 10
Helsinki 9
Princeton 8
Brooklyn 6
Charlotte 6
Dublin 6
Paris 6
Wilmington 6
Baghdad 5
Hillsboro 5
Las Vegas 5
Mexico City 5
Benin City 4
Casablanca 4
Kingston 4
Lawrence 4
London 4
Nanjing 4
Philadelphia 4
Phoenix 4
Rio de Janeiro 4
Turin 4
Belgrade 3
Belo Horizonte 3
Cairo 3
Da Nang 3
Dammam 3
Doha 3
Managua 3
Montreal 3
Phnom Penh 3
Santiago 3
Seattle 3
Staten Island 3
Toronto 3
Acapulco de Juárez 2
Assago 2
Atlanta 2
Bologna 2
Bossier City 2
Cary 2
Catania 2
Caxias do Sul 2
Coral Springs 2
Council Bluffs 2
Curitiba 2
Florence 2
Freehold 2
Fremont 2
Guarulhos 2
Guatemala City 2
Houston 2
Jakarta 2
Jeddah 2
Kolkata 2
Lima 2
Long Xuyen 2
Louisville 2
Manila 2
Maringá 2
Miami 2
Minnetonka 2
Montevideo 2
Mérida 2
Natal 2
Nuremberg 2
Okmulgee 2
Padua 2
Palermo 2
Pasadena 2
Peachtree Corners 2
Piscataway 2
Pune 2
Quito 2
San Diego 2
San Juan 2
San Mateo 2
Sarasota 2
Sparks 2
Taranto 2
Tigard 2
Venice 2
Totale 773
Nome #
The Rare Entity of Basaloid Thymic Carcinoma: A Multicentric Retrospective Analysis from the Italian Collaborative Group for ThYmic MalignanciEs (TYME) 97
Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy 86
Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial 75
Resound Trial: A phase 2 study of regorafenib in patients with thymoma (type B2-B3) and thymic carcinoma previously treated with chemotherapy 59
Clinical management of patients with thymic epithelial tumors: the recommendations endorsed by the Italian Association of Medical Oncology (AIOM) 55
Macrophages and bone metastasis 52
SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis 51
Avelumab combined with axitinib for patients with advanced thymoma B3 and thymic carcinoma 44
Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research 43
Muscle and Muscle-like Autoantigen Expression in Myasthenia Gravis Thymus: Possible Molecular Hint for Autosensitization 37
Bridging Knowledge Gaps in Small Cell Lung Cancer: Data, Challenges and Priorities 35
Lower incidence of COVID-19 in patients with inflammatory bowel disease treated with non-gut selective biologic therapy 34
Correlation between treatments and outcomes of patients with EGFR-mutated non-small-cell lung cancer that transitioned into small-cell lung cancer: an international retrospective study 34
Continuous sunitinib schedule in advanced platinum refractory thymic epithelial neoplasms: A retrospective analysis from the ThYmic MalignanciEs (TYME) Italian collaborative group 32
Patients with locally advanced and metastatic cutaneous squamous cell carcinoma treated with immunotherapy in the era of COVID-19: stop or go? Data from five Italian referral cancer centers 31
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. 28
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. 28
Baseline neutrophil-to-lymphocyte ratio (NLR) is associated with outcome of patients treated with BRAF inhibitors 24
Course of Sars-CoV2 Infection in Patients with Cancer Treated with anti-PD-1: A Case Presentation and Review of the Literature 20
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis 20
Comparison of filgrastim and pegfilgrastim prophylaxis in sarcoma patients receiving highly myelosuppressive chemotherapy 19
Aprepitant use during chemotherapy and association with survival in women with early breast cancer 19
A phase II study of regorafenib in patients with thymic epithelial tumours previously treated with chemotherapy 19
Differential activity of avapritinib in patients with metastases from mucosal melanoma and thymic carcinoma harbouring KIT exon 17 mutations: Initial experience from a Compassionate Use Program in Italy 17
Boosting anticancer immunotherapy through androgen receptor blockade 17
Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study 16
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy 16
Outcomes of patients with advanced solid tumors who discontinued immune-checkpoint inhibitors: a systematic review and meta-analysis 16
“Heterogeneity of treatment effect on patients’ long-term outcome according to pathological response type in neoadjuvant RCTs for breast cancer.” 15
Primary malignant phyllodes tumors of the breast: A retrospective analysis from a referral center 14
Biological and clinical features of early triple-negative invasive lobular carcinomas of the breast 14
Data of Italian Cancer Centers from two regions with high incidence of SARS CoV-2 infection provide evidence for the successful management of patients with locally advanced and metastatic melanoma treated with immunotherapy in the era of COVID-19 14
Sex-based differences of the tumor mutational burden and T-cell inflammation of the tumor microenvironment 14
Sex hormones, the anticancer immune response, and therapeutic opportunities 14
Metaplastic breast cancer: Prognostic and therapeutic considerations 13
Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E 13
Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations 13
Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity 13
Successful treatment with avapritinib in patient with mucosal metastatic melanoma 13
Sex-based dimorphism of anticancer immune response and molecular mechanisms of immune evasion 12
Association of Anticancer Immune Checkpoint Inhibitors With Patient-Reported Outcomes Assessed in Randomized Clinical Trials A Systematic Review and Meta-analysis 12
Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer Critical Analysis of Strengths, Weaknesses, and Misinterpretations 11
Metaplastic breast cancers and triple-negative breast cancers of no special type: are they prognostically different? A systematic review and meta-analysis 10
Differential activity of avapritinib in patients with metastases from mucosal melanoma and thymic carcinoma harbouring KIT exon 17 mutations: Initial experience from a Compassionate Use Program in Italy 10
Pharmacological inhibition of LSD1 triggers myeloid differentiation by targeting GSE1 oncogenic functions in AML 10
Sex and cancer immunotherapy: Current understanding and challenges 9
Xpo1 Inhibition: A Promising Therapeutic Strategy in Thymic Epithelial Tumors 9
The rare entity of gastrointestinal leiomyosarcomas: An Italian multicenter retrospective study in high‐volume referral centers 9
Estrogen Signaling in Early-Stage Breast Cancer: Impact on Neoadjuvant Chemotherapy and Immunotherapy 9
Ethnicity-based differences in breast cancer features and responsiveness to CDK4/6 inhibitors combined with endocrine therapy 9
Different Response to Immunotherapy According to Melanoma Histologic Subtype 9
Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma 9
High-dose continuous-infusion ifosfamide in advanced thymic epithelial Tumors: A TYME network study 8
Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors ceritinib 8
Sex as a predictor of response to cancer immunotherapy Reply 8
EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lung 8
Under-representation of women in Randomized Clinical Trials testing anticancer immunotherapy may undermine female patients care. A call to action 8
Sex-related differences in patients with coronavirus disease 2019: results of the Cardio-COVID-Italy multicentre study 7
Thymic epithelial tumors: From biology to treatment 7
Epstein-Barr virus in tumor-infiltrating B cells of myasthenia gravis thymoma: an innocent bystander or an autoimmunity mediator? 7
Extensive vitiligo associated to response to c-kit inhibitor in metastatic mucosal melanoma 7
Primary ipilimumab/nivolumab followed by adjuvant nivolumab in patients with locally advanced or oligometastatic melanoma: Update on outcome 7
Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trials 7
Improved outcomes in women with BRAF-mutant melanoma treated with BRAF/MEK-targeted therapy across randomized clinical trials. A systematic review and meta-analysis 7
Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence 7
Original Research Thymic carcinoma with Lynch syndrome or microsatellite instability, a rare entity responsive to immunotherapy 7
Sex Differences in Efficacy and Toxicity of Systemic Cancer Treatments: Role of the Microbiome 7
Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis 7
Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice 7
The effect of patient sex on the efficacy and safety of anticancer immunotherapy 7
Immune-checkpoint inhibitors in anal squamous cell carcinoma: a systematic review and meta-analysis 7
Targeting ALK in patients with advanced Non Small Cell Lung Cancer: Biology, diagnostic and therapeutic options 7
Primary ipilimumab/nivolumab immunotherapy followed by adjuvant nivolumab in patients with locally advanced or oligometastatic melanoma: Update on outcome 6
Sex-based dimorphism in the SARS-CoV2 virulence 6
EPIDERMAL GROWTH FACTORS TYROSINE-KINASE INHIBITORS (EGFR-TKI) EFFICACY IN NSCLC PATIENTS WITH HIGH POLYSOMY OF CHROMOSOME 7 AND EGFR/KRAS WILD TYPE TUMORS 6
Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta-analysis of randomized clinical trials 6
Editorial: Differential Efficacy of Immune Checkpoint Inhibitors due to Age and Sex Factors 6
Exemestane Plus Ovarian Function Suppression Is the Best Adjuvant Treatment of Premenopausal Women With Endocrine-Responsive Breast Cancer at Higher Risk of Relapse and With HER2-Negative Tumors 6
Sex-based differences of the intratumoral immune-infiltrate 6
Investigational drugs for the treatment of thymic cancer: a focus on phase 1 and 2 clinical trials 6
Effectiveness of intensive clinical and radiological follow-up in patients with surgically resected NSCLC. Analysis of 2661 patients from the prospective MAGRIT trial 6
EGFR-TKI Plus Anti-Angiogenic Drugs in EGFR-Mutated Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials 6
Metaplastic breast cancers and triple-negative breast cancers of no special type: are they prognostically different? A systematic review and meta-analysis 5
Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis 5
Gender-Based Differences in the Efficacy of Anti-EGFR/BRAF/MEK Targeted Therapy in Patients with BRAF-Mutated Metastatic Colorectal Cancer 5
Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors 5
Molecular Pathways: Anticancer Activity by Inhibition of Nucleocytoplasmic Shuttling 5
Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer 5
Exon-18-EGFR Mutated Transformed Small-Cell Lung Cancer: A Case Report and Literature Review 5
Genetic Alterations of Melanoma Brain Metastases: A Systematic Review and Meta-Analysis 5
Erlotinib Efficacy in NSCLC Patients with High Polysomy of Chromosome 7 and EGFR/KRas Wild-Type Tumors 4
PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors 4
Exon-18-EGFR Mutated Transformed Small-Cell Lung Cancer: A Case Report and Literature Review 4
Extended Endocrine Therapy and Survival for Breast Cancer Subtypes in Premenopausal Patients 4
Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials 3
Molecular features and clinical outcome of lung malignancies in very young people 3
Pathological and clinical features of enteric adenocarcinoma of the thymus. A pooled analysis of cases from a reference center and systematic review of the literature 3
Totale 1.572
Categoria #
all - tutte 14.451
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.451


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202221 0 1 0 2 0 0 0 4 3 2 9 0
2022/202358 9 0 4 7 3 5 0 5 12 6 6 1
2023/202446 0 6 7 1 0 9 6 4 0 1 5 7
2024/2025124 5 2 1 1 0 11 11 12 15 29 14 23
2025/20261.143 42 17 17 53 21 23 96 315 144 101 65 249
2026/2027161 124 37 0 0 0 0 0 0 0 0 0 0
Totale 1.572